Abstract:BACKGROUND:Real-time quantitative RT-PCR (RQ-PCR) assay has become a vital tool to monitor residual disease of leukemia. However, the complexity and standardization of RQ-PCR should never be overlooked and the results should be interpreted cautiously in clinical conditions. We aimed to assess the methodology of RQ-PCR and its clinical applications in monitoring molecular kinetics of 36 newly diagnosed cases of acute promyelocytic leukemia patients with t (15; 17) from October 2004 to December 2005.METHODS:All the TaqMan probe-based RQ-PCR reactions and analysis were performed on an ABI-PRISM 7,500 platform. The quantitation of PML-RARalpha transcripts was represented by the normalized quotient, that is, PML-RARalpha transcript copies divided by ABL transcript copies. According to induction therapy, the patients were classed into two groups: group 1 (n = 23), three-drug combination including arsenics, all-trans retinoic acid and mitoxantrone; and group 2 (n = 13), two-drug combination from all-trans retinoic acid, arsenics and mitoxantrone.RESULTS:The sensitivity of RQ-PCR was 1 per 10(5) cells and 5 copies of the PML-RARalpha transcript could be reproducibly detected. No false positive results occurred in 40 non-acute promyelocytic leukemia samples. Optimal amplification efficiency could be attained, which was determined by the slope of the standard curves (slope: -3.2 - -3.7). The inter-assay and intra-assay variation coefficients of the method were 1.01% and 0.56% respectively. Although the time to attain hematological complete remission was similar in both groups, the time to achieve molecular remission of group 1 was significantly shorter than that of group 2 (61 days vs 75 days, P = 0.034). The rate of molecular remission within 70 days was higher in group 1 than in group 2 (75.00% vs 38.46%, P = 0.036). Compared with pretreatment, median reduction of the PML-RARalpha transcript before first consolidation therapy differed significantly between group 1 and group 2 (log scale, 3.15 vs 2.31, P = 0.024). Interestingly, we found that PML-RARalpha transcript levels temporarily increased in bone marrow (7 patients) and peripheral blood (22 patients) samples of patients during induction therapy in both groups.CONCLUSIONS:The RQ-PCR assay is reliable for the detection of PML-RARalpha transcripts. Arsenics, all-trans retinoic acid and mitoxantrone triad induction treatment of acute promyelocytic leukemia is superior to two-drug combination induction therapy in terms of the molecular response.

Retinoic Acid-Induced Gene G(RIG-G) as a Novel Monitoring Biomarker in Leukemia and Its Clinical Applications

Establishment and evaluation based of a RIG-G gene detection system by TaqMan-MGB probe real-time PCR

Clinical Application of Detection of the Fusion Gene in Acute Promyelocytic Leukemia with Reverse-Transcriptase Real-Time Quantitative PCR

Detecting PML-RARα Transcript in Acute Promyelocytic Leukemia Using Real-Time Quantitative RT-PCR

Feasibility and clinical significance of real-time quantitative RT–PCR assay of PML-RARα fusion transcript in patients with acute promyelocytic leukemia

[Detection of PML/RARalpha Gene Transcripts in 46 Newly Diagnosed Acute Promyelocytic Leukemia Patients by Real-Time Quantitative Reverse-Transcription Polymerase Chain Reaction].

[Molecular responses in acute promyelocytic leukemia patients monitored by real-time quantitative RT-PCR]

Functional Study On Several Novel Retinoic Acid Induced Genes (Rigs).

Development and Validation of A 3-Plex Rt-Qpcr Assay for the Simultaneous Detection and Quantitation of the Three Pml-Rara Fusion Transcripts in Acute Promyelocytic Leukemia

Regulation Mechanism for Rig-g Gene Expression Induced by All-trans Retinoic Acid

Immunofluorescence for dynamic monitoring of PML-RARα fusion protein in patients with acute promyelocytic leukemia

Acute Promyelocytic Leukemia: Clinical Relevance of Two Major PML-RAR Alpha Isoforms and Detection of Minimal Residual Disease by Retrotranscriptase/polymerase Chain Reaction to Predict Relapse.

Real-time Quantitative Polymerase Chain Reaction for Dynamic Monitoring of Minimal Residual Disease in Acute Promyelocytic Leukemia after Treatment

RIG-G inhibits the proliferation of NB4 cells and propels ATRA-induced differentiation of APL cells

Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia

Immunophenotypic Analysis and Rapid Diagnosis of Acute Promyelocytic Leukemia by Flow Cytometry.

Detection of WT1 gene in acute myeloid leukemia children by real-time fluorescent quantitative RT-PCR and its clinical significance]

PML/RARα Fusion Gene Detection by Fluorescence in Situ Hybridization Technique in the Diagnosis and Efficacy Evaluation of Patients with Acute Promyelocytic Leukemia

Detection of Pml-Rar Alpha in Patients with Apl During Follow-Up Period

Significance of kinetic detection of the PML-RARα fusion gene in children with acute promyelocytic leukemia

Circulating lnc-LOC as a novel noninvasive biomarker in the treatment surveillance of acute promyelocytic leukaemia